If exercising is not in the books for you, then you should finish up your weight-loss journey with an EMSCULPT NEO treatment instead
The Danish Patient Compensation Association has announced that it will compensate at least four patients who lost their vision after taking Wegovy and another GLP-1
If approved for the new indication, it could add a major new growth driver for semaglutide, which is already seeing sales rocket on the back of its use as Ozempic for diabetes, Wegovy for obesity, and label extensions for both brands for cardiovascular risk reduction in certain high-risk patient groups
(Retatrutide discovery) Jastreboff AM, et al
Ozempic rose from a 10 th place ranking among the 10 top-selling Part D drugs in 2021, with gross spending of $2.6 billion, to 6 th place in 2022, with spending of $4.6 billion (Figure 2)
Clinical trials suggest people eat fewer calories while on semaglutide, with many showing a reduced desire for high-fat meals
